Nanobiotix Stock Rebounds 4.69% Mid-Session After Two Days of Decline

Recent Financial Developments and Market Response

The day before, Nanobiotix had lost 5.43% after updating on its activities and cash position. However, this technical rebound is part of a remarkable medium-term dynamic: the stock has shown an increase of 142.7% over three months and a spectacular surge of 454.7% over a year, significantly outperforming the CAC 40, which only recorded a rise of 12.65% over the same period. Over the past week, however, the stock has seen a decline of 3.56%, reflecting a consolidation phase after its rapid ascent. Trading volumes this Thursday remain moderate, with 0.39% of the capital changing hands, reflecting some caution from investors in a Parisian market itself slightly up by 0.1%. A few days ago, Nanobiotix announced the closing of a non-dilutive financing agreement for royalty sharing with Healthcare Royalty for an amount that could reach 71 million dollars, triggering an initial payment of 50 million dollars. The company expects an additional payment of 21 million dollars one year after this closing, under certain conditions, extending its cash horizon until the beginning of 2028. This announcement, intended to reassure the market about the financial solidity of the biotech, was not enough to prevent the correction of the last two sessions, suggesting that investors had already integrated this information or that a natural profit-taking was underway after the exceptional rise in recent months.

Technical Analysis and Stock Movement

From a technical standpoint, Nanobiotix's stock is currently slightly above its 50-day moving average established at 17.67 euros, signaling a medium-term trend that remains constructive despite recent volatility. The price is in an intermediate zone between a robust support identified at 13.36 euros and a major psychological resistance at 23.75 euros, leaving a margin of progression of 33% before testing this technical ceiling. This median position offers the stock some latitude for movement in both directions, especially as the one-month volatility reaches 28.67%, characteristic of biotechnological stocks subject to the vicissitudes of clinical announcements. The RSI (Relative Strength Index) stands at 48, a neutral level confirming that the stock is neither in an overbought nor oversold situation, thus allowing a technical rebound movement without major constraint. The significant gap with the 200-day moving average, which stands at 7.81 euros, reflects the spectacular acceleration of the price since the beginning of the year. This significant divergence materializes the enthusiasm of investors around the company's clinical pipeline and its strategic partnerships, notably with Johnson & Johnson for the development of its candidate JNJ-1900.

Market Capitalization and Future Prospects

Nanobiotix's market capitalization, now close to 860 million euros, reflects market expectations regarding the potential of its hafnium oxide nanoparticle-based radiosensitizer NBTXR3. The company recently announced progress in the global development program of JNJ-1900 with the first Phase 1 data in esophageal cancer and the completion of the transfer of sponsorship of NANORAY-312 to Johnson & Johnson in the majority of countries. As of September 30, 2025, the company had cash and cash equivalents of 20.4 million euros, an amount now considerably strengthened by the financing from Healthcare Royalty. This Thursday's rebound, although modest, illustrates the resilience of a stock that continues to attract investors positioned on clinical speculation, in anticipation of the next data expected in 2026 regarding several Phase 1 studies in different oncological indications.